126802-52-6

Usage

Uses

Used in Pharmaceutical Research:
2-Methyl-2-(2-nitrophenyl)propanoic acid is used as a research tool for investigating the pharmacology of prostaglandins, which are important in various physiological processes and are targeted by non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.
Used in Anti-inflammatory Applications:
In the pharmaceutical industry, 2-Methyl-2-(2-nitrophenyl)propanoic acid is used as an anti-inflammatory agent due to its potential to modulate the inflammatory response, similar to its parent compound ibuprofen.
Used in Analgesic Applications:
2-Methyl-2-(2-nitrophenyl)propanoic acid is also used as an analgesic agent, leveraging its capacity to alleviate pain, which is a common characteristic of NSAIDs.
These applications highlight the compound's versatility in medicinal chemistry and its potential to contribute to the development of new therapeutic agents.

InChI:InChI=1/C10H11NO4/c1-10(2,9(12)13)7-5-3-4-6-8(7)11(14)15/h3-6H,1-2H3,(H,12,13)

Upstream product

• 136764-87-9 2-methyl-2-(2-nitro-phenyl)-propionic acid methyl ester 
• 1195-98-8 2-methyl-2-phenylpropionitrile 
• 71825-51-9 4-(2-cyanoprop-2-yl)-1-nitrobenzene 

Downstream Products

• 1056427-10-1 2,2-dimethyl-2-(2-nitrophenyl)acetyl chloride 
• 154078-38-3 N-<4-(methylcarbonyl)phenyl>-2-methyl-2-(2-nitrophenyl)propanamide 
• 154078-37-2 N-<4-(methylsulfonyl)phenyl>-2-methyl-2-(2-nitrophenyl)propanamide 
• 154078-34-9 N-(3-quinolyl)-2-methyl-2-(2-nitrophenyl)propanamide 
• 154078-32-7 N-(4-methoxyphenyl)-N-2-methyl-2-(2-nitrophenyl)propanamide 
• 154078-36-1 N-<4-(dimethylamino)phenyl>-2-methyl-2-(2-nitrophenyl)propanamide 
• 154078-50-9 N-(2-phenylethyl)-2-methyl-2-(2-nitrophenyl)propanamide 
• 154078-29-2 N-(4-methoxyphenyl)-2-methyl-2-(2-nitrophenyl)propanamide 
• 154078-60-1 2-(2-Amino-phenyl)-N-(4-methoxy-phenyl)-N-methyl-isobutyramide 

Relevant academic research and scientific papers

5'-[2-(2-Nitrophenyl)-2-methylpropionyl]-2'-deoxy-5-fluorouridine as a potential bioreductively activated prodrug of FUDR: Synthesis, stability and reductive activation

5'-[2-(2-Nitrophenyl)-2-methylpropionyl]-2'-deoxy-5-fluorouridine was synthesized as a potential bioreductively activated prodrug of 5-fluoro-2'-deoxyuridine (FUDR). The target compound was stable in both phosphate buffer and human serum and was found to

The 2,2-Dimethyl-2-(ortho-nitrophenyl)acetyl (DMNPA) Group: A Novel Protecting Group in Carbohydrate Chemistry

The 2,2-dimethyl-2-(ortho-nitrophenyl)acetyl (DMNPA) group was introduced to synthetic carbohydrate chemistry as a protecting group (PG) for the first time. Benefiting from a unique chemical structure and novel deprotection conditions, the DMNPA group can be cleaved rapidly and mutually orthogonal to other PGs. Orchestrated application of the DMNPA group with other PGs led to the highly efficient synthesis of the glycan of thornasterside A.

Method for preparing and removing saccharide hydroxyl protecting group dimethyl phenylacetyl DMNA

The invention relates to a method for preparing and removing saccharide hydroxyl protecting group dimethyl phenylacetyl DMNA. The method comprises the following steps: (1) efficiently introducing saccharide hydroxyl protecting group dimethyl phenylacetyl into saccharide hydroxyl; and (2) efficiently removing a hydroxyl protecting group shown in the description. The method is environmentally friendly and has the advantages that the advantages that the preparation is simple, the introduction is efficient, the operation is easy, the removal is efficient, and the application range is wide; and furthermore, a protecting group has very good stereoselectivity when being used for protecting 2-hydroxyl of a glycosyl donor, so that the development and application of the protecting group are promoted.

Azo-reductase activated budesodine prodrugs for colon targeting

Budesodine is a synthetic glurocorticoid that undergoes substantial first pass metabolism, limiting systemic exposure. Its use in treatment of inflammatory bowel disease would benefit from a targeting strategy that could lead to a local topical effect, improving safety and increasing anti-inflammatory efficacy. A two-step prodrug strategy involving azoreduction/cyclization that we developed previously for prednisolone is here applied with some variations to budesonide. The budesodine prodrugs were tested using an in vitro azoreductase assay simulating human colonic microflora. The kinetics of amino steroid ester cyclization and its pH dependence was also evaluated. The stability of the prodrugs systems in simulated human duodenal and gastric fluid was evaluated to determine the likelihood of intact intestinal transit. The propionic acid derived prodrug 3 undergoes rapid activation by Clostridium perfingens and its putative reduction product cyclizes with acceptable rapidity when synthesized independently. These properties of 3 suggest that it has potential in management of ulcerative colitis.

Palladium-catalyzed decarboxylative coupling of potassium nitrophenyl acetates with aryl halides

A palladium-catalyzed decarboxylative cross-coupling of potassium 2- and 4-nitrophenyl acetates with aryl chlorides and bromides has been developed. Because the nitro group can be readily converted to many other functional groups, the new reaction provides a useful method for the preparation of diverse 1,1-diaryl methanes and their derivatives.

PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS

The present invention relates to novel compounds that are CGRP receptor antagonists, processes for their preparation, to compositions containing them and to their use in the treatment of migraine, headache, and cluster headache.

5′-(2-Nitrophenylalkanoyl)-2′-deoxy-5-fluorouridines as potential prodrugs of FUDR for reductive activation

Four 5′-(2-nitrophenylalkanoyl)-2′-deoxy-5-fluorouridines (1a-d) were designed and synthesized as potential prodrugs of FUDR for reductive activation. Two methyl groups were introduced α to the ester carbonyl to increase both the rate of cyclization activation and the stability of the conjugates towards serum esterases. Chemical reduction of the nitro group into an amino leads to cyclization and release of the active FUDR. Kinetic analysis of the cyclization activation process indicates that the two methyl groups α to the ester carbonyl restrict the rotational freedom of ground state molecule and promote the cyclization reaction. However, the two methyl groups also were found to render the conjugates as poor substrates of E. coli B nitroreductase. Conjugate 1c, without the two methyl groups, was reduced by E. coli B nitroreductase (t1/2=8 h) to give two products, a N-hydroxyl lactam and the drug FUDR, suggesting that the enzymatic reduction and subsequent cyclization activation proceeded through the hydroxylamine intermediate. These results indicate that cyclization activation will occur once the nitro group is reduced either to an amino or to a hydroxylamino group. The fact that the amino intermediates cyclized easily to release the incorporated drug FUDR suggests the feasibility of using peptide-linked acyl 2-aminophenylalkanoic acid esters as potential prodrugs for proteolytic activation.

Relationships between Structure and Kinetics of Cyclization of 2-Aminoaryl Amides: Potential Prodrugs of Cyclization-Activated Aromatic Mustards

2-Nitroaryl amides of general structure I are proposed as bioreducible prodrugs, capable of releasing cytotoxic aminoaniline mustards V on bioactivation by spontaneous cyclization of the resulting 2-aminoaryl amides II via a tetrahedral intermediate, III.